 This study is the first-time-in-patient trial of GSK1399686, a novel locally-acting anti-inflammatory compound, aimed at obtaining initial information on the tolerability, safety, pharmacokinetics including concentrations in colon mucosa and anti-inflammatory activity of GSK1399686 upon oral dosing in patients with active ulcerative colitis. 